Peptika.
Cat. 03
Type I · Lyophilised
PK-2026-CJC-12
Peptika CJC-1295 vial
Lot-tracedEU pharmacyCold-chain 2–8 °C
N° 03 · Growth Hormone

CJC-1295.

GHRH analogue — DAC variant gives sustained release, NO-DAC mimics native pulsatility.

Select strengthPer-vial price
Quantity
1
Total
€80.00· 1 vial
Combination presets

Pre-compounded multi-peptide vials. An EU-licensed physician reviews the blend and dosing — anything they decline is refunded.

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

  • ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
  • ✓Patient-named prescription only — dispensed against a valid Rx.
  • ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
  • ✓Cold-chain shipping across EU/EEA — 2–5 working days.
Overview

About CJC-1295.

CJC-1295 is a modified GHRH analogue with two main variants in clinical use. The NO-DAC version (often called Mod-GRF 1-29) has a half-life similar to native GHRH and is used to mimic the physiological pulsatile pattern. The DAC version is conjugated with a Drug Affinity Complex (DAC) molecule that binds albumin, extending the half-life to approximately 8 days.

DAC is convenient (one or two injections per week) but the sustained release creates a continuous 'GH bleed' rather than physiological pulses. Modern practice tends to favour NO-DAC stacked with Ipamorelin to preserve pulsatility — but the trade-off is your physician's call.

Mechanism of action

Activation of pituitary GHRH receptors increases cAMP and triggers GH release. DAC variant binds circulating albumin via a maleimidopropionyl-amino-acid linker, slowing renal clearance and extending the half-life from minutes to days.

Posology · for information only

NO-DAC: subcutaneous injection 100–200 mcg, 1–3 times per day, often stacked with Ipamorelin. DAC: subcutaneous injection 1–2 mg once weekly or twice weekly. Always per physician prescription.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence baseClinical RCT evidence
Indications studied
Sustained GH supportBody compositionRecovery
Selected references
  1. 01Teichman SL, et al. — Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab · 2006 · doi: 10.1210/jc.2005-1480
Identification & specifications
INN / Name
CJC-1295
Form
Lyophilised vial · subcutaneous injection
Strength
DAC · 5mg vial
Manufacturing
EU-GMP Annex 1 · Grade A/B
Endotoxins
European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity
HPLC + MS · > 98%
Cold chain
Validated 2–8 °C, monitored end-to-end
Regulatory basis
Directive 2001/83/EC · Article 5(1)
Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Growth Hormone.

All Growth Hormone preparations
Pre-compounded

Combinations with CJC-1295.